GURUFOCUS.COM » STOCK LIST » USA » NAS » Incyte Corp (NAS:INCY) » Definitions » E10
Switch to:

Incyte E10

: $0.45 (As of Jun. 2022)
View and export this data going back to 1993. Start your Free Trial

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Incyte's adjusted earnings per share data for the three months ended in Jun. 2022 was $0.720. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.45 for the trailing ten years ended in Jun. 2022.

As of today (2022-09-27), Incyte's current stock price is $66.44. Incyte's E10 for the quarter that ended in Jun. 2022 was $0.45. Incyte's Shiller PE Ratio of today is 147.64.

During the past 13 years, the highest Shiller PE Ratio of Incyte was 249.60. The lowest was 147.07. And the median was 202.51.


Incyte E10 Historical Data

The historical data trend for Incyte's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
E10
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.88 -0.62 -0.18 -0.29 0.30

Incyte Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
E10 Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.01 0.30 0.37 0.45

Competitive Comparison

For the Biotechnology subindustry, Incyte's E10, along with its competitors' market caps and E10 data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Incyte E10 Distribution

For the Biotechnology industry and Healthcare sector, Incyte's E10 distribution charts can be found below:

* The bar in red indicates where Incyte's E10 falls into.



Incyte E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted earnings per share data for the three months ended in Jun. 2022 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2022 (Change)*Current CPI (Jun. 2022)
=0.72/125.0168*125.0168
=0.720

Current CPI (Jun. 2022) = 125.0168.

Incyte Quarterly Data

per share eps CPI Adj_EPS
201209 -0.170 97.633 -0.218
201212 0.140 96.871 0.181
201303 -0.120 98.209 -0.153
201306 -0.020 98.518 -0.025
201309 -0.140 98.790 -0.177
201312 -0.260 98.326 -0.331
201403 -0.210 99.695 -0.263
201406 -0.220 100.560 -0.274
201409 0.330 100.428 0.411
201412 -0.220 99.070 -0.278
201503 -0.110 99.621 -0.138
201506 0.050 100.684 0.062
201509 -0.220 100.392 -0.274
201512 0.290 99.792 0.363
201603 0.120 100.470 0.149
201606 0.180 101.688 0.221
201609 0.190 101.861 0.233
201612 0.050 101.863 0.061
201703 -0.960 102.862 -1.167
201706 -0.060 103.349 -0.073
201709 0.170 104.136 0.204
201712 -0.710 104.011 -0.853
201803 -0.190 105.290 -0.226
201806 0.240 106.317 0.282
201809 0.140 106.507 0.164
201812 0.320 105.998 0.377
201903 0.470 107.251 0.548
201906 0.480 108.070 0.555
201909 0.590 108.329 0.681
201912 0.510 108.420 0.588
202003 -3.330 108.902 -3.823
202006 1.320 108.767 1.517
202009 -0.070 109.815 -0.080
202012 0.680 109.897 0.774
202103 0.240 111.754 0.268
202106 0.670 114.631 0.731
202109 0.820 115.734 0.886
202112 2.540 117.630 2.700
202203 0.170 121.301 0.175
202206 0.720 125.017 0.720

Add all the adjusted EPS together and divide 10 will get our e10.


Incyte  (NAS:INCY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Incyte's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=66.44/0.45
=147.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Incyte was 249.60. The lowest was 147.07. And the median was 202.51.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Incyte E10 Related Terms

Thank you for viewing the detailed overview of Incyte's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte Business Description

Incyte logo
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Executives
Tray Thomas officer: Principal Accounting Officer C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Brawley Otis W director 5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518
High Katherine A director 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Harrigan Edmund director
Morrissey Michael James officer: EVP, Head of Tech. Operations IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Dickinson Jonathan Elliott officer: EVP, General Manager, Europe CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Stamoulis Christiana officer: EVP & Chief Financial Officer C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139
Dhanak Dashyant officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Pasquale Maria E officer: EVP & General Counsel C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Fouse Jacqualyn A director C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108
Iyengar Vijay K officer: EVP GPS, BD, & Licensing 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Stein Steven H officer: EVP & Chief Medical Officer 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Trower Paul officer: VP, Finance & Prin Acc Officer 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Clancy Paul J director C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Bienaime Jean Jacques director 925 PAGE MILL ROAD PALO ALTO CA 94304

Incyte Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)